Clinical trial NCT00358293: Study of Nighttime Dosing of Sublingual Tizanidine (12 mg) in Multiple Sclerosis (MS) Patients With Significant Spasticity
Official title: A Double-Blind, Randomized, Crossover Study to Evaluate the Clinical Efficacy and Safety of Oral Tizanidine HCl (12 mg) Versus Novel Sublingual Tizanidine HCl (12 mg) for the Treatment of Spasticity in MS Patients
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
PHASE2
Conditions: Muscle Spasticity
Keywords: Multiple Sclerosis
Spasticity
Sublingual Tizanidine
Ashworth Scores
Spasticity in Multiple Sclerosis Patients
Lead sponsor: Teva GTC
Sponsor class: INDUSTRY
First posted: 2006-07-31
Enrollment: 20
Sex: ALL
Minimum age (years): 20
Maximum age (years): 65
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: RANDOMIZED
Intervention model: CROSSOVER
Primary purpose: TREATMENT

Brief summary: Nightly administration of 8 mg of a unique sublingual (under the tongue) formulation of tizanidine, a known anti-spasticity medication, has been shown in a previous study to improve next-day spasticity, about 12 hours following dosing in 20 multiple sclerosis (MS) patients. This improvement was statistically significant when compared to oral tizanidine dosing. The current study is being undertaken to see if increasing the dose to 12 mg once nightly will result in an even greater improvement, with a longer effect, i.e., next day improvement in spasticity both in the morning as well as in the late afternoon.

Detailed description: Sublingual tizanidine, a novel test formulation of the known effective antispasticity agent, has been shown to have a unique pharmacokinetic profile \[(i.e., nearly twice the bioavailability/AUC), but with little or no increase in peak plasma levels (Cmax) as compared to oral tizanidine (Zanaflex)\]. When administered nightly to 20 MS patients, at a dose of 8 mg, it was shown to improve next-day spasticity (statistically significant improvement in Ashworth scores) about 12 hours post-dosing), improvement in nighttime (first quartile) sleep efficiency (as demonstrated by actigraphic measurement), and no increase in daytime somnolence.

Current study is being undertaken to evaluate if increased dosing (12 mg once nightly) of sublingual tizanidine (vs. oral) will show a concomitant increase in clinical effect, i.e., longer improvement, with next-day spasticity score improvement both in AM (as previously) as well as at PM (late afternoon) evaluation, with no increase in daytime somnolence.

Eligibility criteria: Inclusion Criteria:

* Male and female patients between the ages of 20-65
* Definitive diagnosis of MS, with Expanded Disability Status Scale (EDSS) less than 6.5 at screening
* Has significant spasticity (total Ashworth =\> 6) at screening
* Can maintain sleep regimens of at least 5 hours nightly for study duration
* May be allowed to take other anti-spasticity medication during study (including oral baclofen) as per individual dosing regimen, with the following qualifications:

  * No dose after 6pm on any study day
  * No dose at all on a clinic evaluation day (Visits 3, 4, 5)
* Females must agree to use a medically accepted form of birth control, be surgically sterile, or be two years post-menopausal. Oral contraception is contraindicated with tizanidine use.

Exclusion Criteria:

* Acute MS exacerbation requiring treatment with steroids within 30 days of screening
* Initiation of discontinuation of interferon beta within 30 days of screening
* Use of baclofen pump
* Use of CYP1A2 inhibitors during study
* Taking medications that would potentially interfere with the actions of the study medication or outcome variables, including: sedatives, stimulants, anti-hypertensives, tricyclic antidepressants, etc.
* Previous diagnosis of a sleep disorder, distinct from MS, such as obstructive sleep apnea or narcolepsy
* Score \>18 on Beck Depression Inventory at screening
* Changes in chronic oral medications within 2 weeks of baseline and during study
* Significant abnormalities in screening lab parameters (ex: ALT, AST, bilirubin \> 2 x upper limit of normal \[ULN\]; creatinine \> 2 mg/dl; white blood cell \[WBC\] \< 2,300; platelets \< 80,000).
* Previous history of dementia, unstable psychiatric disease, or current signs and symptoms of significant medical disorders such as severe, progressive, or uncontrolled renal, hepatic, hematological, endocrine, pulmonary, cardiac, neurological, or cerebral disease
* History of allergy to tizanidine or any inactive component (including lactose intolerance) of test or reference formulation
* History of substance abuse within the past 12 months
* Within 30 days of baseline, worked a rotating or nighttime shift
* Participation in another clinical trial within 30 days of baseline
* Patients who are uncooperative or unwilling to sign consent form

Primary outcomes:
measure: Clinical efficacy - improvement in next-day spasticity (Ashworth scores)
measure: Safety - no increase in next-day somnolence (measured objectively using PVT psychomotor vigilance task monitoring) and subjectively, using Epworth Sleepiness Scale (ESS) and Fatigue Severity Scale (FSS) questionnaires
Secondary outcomes:
measure: Secondary clinical efficacy - objective measure of sleep (actigraphy measures)
Other outcomes:
Locations:
city: Tel Aviv
country: Israel
facility: Tel Aviv Sourasky Medical Center- Neurology Department
Study officials:
affiliation: Department of Neurology, Tel Aviv Sourasky Medical Center
name: Arnon Karni, MD
role: PRINCIPAL_INVESTIGATOR
References: